Core Viewpoint - Hainan Haiyao has reported significant financial losses in its 2024 annual report, with a revenue decline of 33% and a net profit loss of approximately 1.53 billion yuan, marking a troubling trend of negative net profits for eight consecutive years [2][10][11]. Financial Performance - The company achieved a revenue of approximately 990.7 million yuan in 2024, down from 1.48 billion yuan in 2023, representing a 33% decrease [5][10]. - The net profit attributable to shareholders was approximately -1.53 billion yuan, a substantial increase in losses compared to -106.5 million yuan in 2023 [5][10]. - The company's cash flow from operating activities was -17.55 million yuan, a decline of 116.95% year-on-year [11]. - The asset-liability ratio reached 90.34%, an increase of 28.83% compared to the previous year, indicating worsening financial health [11]. Business Overview - Hainan Haiyao's main business focuses on the health industry, including intermediates, raw materials, chemical preparations, modern traditional Chinese medicine, and medical services [6]. - The company has three production bases located in Jiangsu, Chongqing, and Hainan, and has a full industrial chain production capability for its anti-infection drugs [6]. Challenges and Issues - The company has faced continuous revenue decline since 2018, with revenues dropping from a peak of 2.47 billion yuan in 2018 to 990.7 million yuan in 2024 [6][10]. - Hainan Haiyao has reported significant asset impairment and credit impairment losses totaling 7.49 billion yuan, raising concerns about asset quality [10]. - The company has been under regulatory scrutiny due to compliance issues, leading to fines and required corrections [14][15]. Future Prospects - Hainan Haiyao is attempting to accelerate its R&D efforts, with ongoing clinical trials for innovative drugs and plans for new product registrations [12]. - The company has also engaged in asset disposals to improve cash flow, but these measures are seen as insufficient to address the broader financial challenges [13]. - The management changes and ongoing compliance issues pose additional risks to the company's recovery efforts [14][15].

北京大成（海口）律师事务所 关于海南海药股份有限公司2025年第二次临时股东大会的 法 律 意 见 书 大成 is Dentons' Preferred Law Firm in China. 北京大成（海口）律师事务所 1 / 7 北京大成（海口）律师事务所 关于海南海药股份有限公司2025年第二次临时股东大会 的法律意见书 致：海南海药股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民 共和国公司法》（以下简称"《公司法》"）和中国证券监督管理委员会《上市 公司股东会规则》（以下简称"《股东会规则》"）等法律、 法规和其他有关规范 性文件的要求，北京大成（海口）律师事务所（以下简称"本 所"）接受海南海 药股份有限公司（以下简称"公司"）的委托，指派律师参加公司2025 年第二次 临时股东大会（以下简称"本次股东大会"）。 本所声明：本所律师仅对本次股东大会的召集程序、召开程序、出席会议人员 资格、召集人资格、表决程序、表决结果及会议决议发表法律意见，并不对本次股 东大会所审议的议案、议案所涉及的事项及内容发表意见。本所律师同意将本法 律意见书随本次股东大会其他信息披露资料一并 ...

证券代码：000566 证券简称：海南海药 公告编号：2025-032 海南海药股份有限公司 2025 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、特别提示： 1、本次股东大会无否决议案的情形； 2、本次股东大会不涉及变更前次股东大会决议的情形。 二、会议召开的情况 1、召开时间： 现场会议召开时间：2025年4月16日下午15：00 网络投票时间：2025年4月16日 （1）通过深圳证券交易所交易系统进行网络投票的时间为：2025年4月16日9：15～ 9：25，9：30～11：30和13：00～15：00； （2）通过深圳证券交易所互联网投票系统投票的时间为：2025年4月16日9:15～ 15:00期间的任意时间。 2、召开地点：海南省海口市秀英区南海大道 192 号海药工业园公司会议室 3、召开方式：采用现场表决与网络投票相结合的方式召开 4、召集人：公司第十一届董事会 5、现场会议主持人：公司第十一届董事会董事长王建平先生 6、公司部分董事、监事和高级管理人员现场或通过视频方式出席了本次股东大会， 北京大成(海口 ...

Core Points - Hainan Haiyao reported a significant decline in revenue and a substantial increase in losses for 2024, with a net profit loss of approximately 1.525 billion yuan, marking a year-on-year increase in losses of 1332.27% [1][2] - The company has faced continuous operational challenges, including a decline in sales across its pharmaceutical and medical service segments, attributed to industry policy changes and reduced demand for certain medications [1][2] - Hainan Haiyao's financial health is deteriorating, with an asset-liability ratio reaching 90.34%, indicating increasing financial risk [3] Revenue Performance - The total revenue for Hainan Haiyao in 2024 was approximately 991 million yuan, a decrease of 33% year-on-year [1] - The pharmaceutical segment generated 794 million yuan, down 38.06%, while medical services brought in 168 million yuan, a decline of 2.57% [1] - The company has experienced a continuous decline in revenue since 2019, with a peak revenue of 2.472 billion yuan in 2018, now reduced to less than 1 billion yuan in 2024 [2] Financial Condition - The company recorded a total of 749 million yuan in impairment provisions for the year, alongside a fair value loss of approximately 400 million yuan [2] - Total expenses, including sales, management, and financial costs, reached 678 million yuan, accounting for 68% of total revenue, with management expenses increasing by 37.14% [2] - The net cash flow from operating activities was negative at -17.55 million yuan, primarily due to increased payment methods and reduced tax refunds [2] Regulatory Issues - Hainan Haiyao has faced multiple regulatory actions due to financial misconduct, including a fine of 2 million yuan for significant disclosure violations [4] - The company was also ordered to rectify issues related to inaccurate financial reporting and improper revenue recognition practices [5] - Despite changes in control and management, ongoing compliance issues indicate persistent internal control weaknesses [4][5]

A股海南自贸区板块异动拉升，海汽集团涨停，海南发展、海南椰岛、凯撒旅业、海南海药、丽尚国潮 等跟涨。消息面上，海南省人民政府办公厅印发《海南省提振和扩大消费三年行动方案》。 订阅A股市场资讯 +订阅 ...

Policy Developments - The National Healthcare Security Administration has established data working groups across all regions, with the aim of enhancing data governance and transparency in healthcare funding [2] Drug and Device Approvals - Jiangsu Tianshili submitted a listing application for the new drug PXT3003, intended for the treatment of Charcot-Marie-Tooth disease type 1A [4] Capital Markets - Ruijian Pharmaceutical completed nearly 100 million RMB in B+ round financing, bringing total financing to over 200 million RMB in less than six months [6] - Weichan Medical announced the completion of several million RMB in angel round financing, aimed at accelerating product development and market entry [7] - Novartis plans to invest $23 billion in the U.S. over the next five years to enhance production capabilities and ensure the domestic supply of critical medications [8] Industry Events - Boya Bio disclosed plans to sell 80% of its subsidiary, Boya Xinha, to focus on its core blood products business, with an initial listing price of 213 million RMB [10] Financial Reports - Pumen Technology reported a revenue of 1.148 billion RMB for 2024, with a net profit of 345 million RMB, reflecting a 5.12% increase [12] - Huaxi Biotechnology's revenue for 2024 was 5.371 billion RMB, down 11.61%, with a net profit of 174 million RMB, down 70.59% [13] - Watson Bio reported a revenue of 2.821 billion RMB for 2024, down 31.41%, with a net profit of 142 million RMB, down 66.10% [14] - Innovation Medical reported a revenue of 816 million RMB for 2024, with a net loss of 93.95 million RMB [15] - People's Tongtai reported a revenue of 10.048 billion RMB for 2024, down 3.29%, with a net profit of 213 million RMB, down 27% [16] - Haizike reported a revenue of 3.721 billion RMB for 2024, with a net profit of 395 million RMB, up 34% [17] - Hainan Haiyao reported a revenue of approximately 999 million RMB for 2024, down 33%, with a net loss of 1.525 billion RMB [18] - Wantai Bio reported a revenue of approximately 2.245 billion RMB for 2024, down 59.25%, with a net profit of 106 million RMB, down 91.49% [19] Public Opinion Alerts - Xinghao Pharmaceutical announced the resignation of director Li Huiqu due to personal reasons, effective April 11, 2025 [21] - Zhaoyan New Drug acknowledged unusual fluctuations in its stock price, linked to a recent FDA plan that may impact the industry [23]

关于海南海药股份有限公司 非经营性资金占用及 其他关联资金往来情况 汇总表的专项审核报告 众环专字(2025)0201915号 目 录 起始页码 专项审核报告 汇总表 非经营性资金占用及其他关联资金往来的情况汇总表 1 海南海药股份有限公司全体股东： 我们接受委托，在审计了海南海药股份有限公司（以下简称"海南海药公司"）2024 年 12 月 31 日合并及公司的资产负债表，2024 年度合并及公司的利润表、合并及公司的现金流 量表和合并及公司的股东权益变动表以及财务报表附注的基础上，对后附的《上市公司 2024 年度非经营性资金占用及其他关联资金往来的情况汇总表》（以下简称"汇总表"）进行了专 项审核。按照中国证券监督管理委员会印发的《上市公司监管指引第 8 号——上市公司资金 往来、对外担保的监管要求》的规定，编制和披露汇总表、提供真实、合法、完整的审核证 据是海南海药公司管理层的责任，我们的责任是在执行审核工作的基础上对汇总表发表专项 审核意见。 我们按照中国注册会计师审计准则的相关规定执行了审核工作。中国注册会计师审计准 则要求我们遵守中国注册会计师职业道德守则，计划和执行审核工作以对汇总表是否不存在 ...

海南海药股份有限公司 审 计 报 告 众环审字(2025)0202061号 目 录 审计报告 | 财务报表 | | | --- | --- | | 合并资产负债表 | 1 | | 合并利润表 | 3 | | 合并现金流量表 | 4 | | 合并股东权益变动表 | 5 | | 资产负债表 | 7 | | 利润表 | 9 | | 现金流量表 | 10 | | 股东权益变动表 | 11 | | 财务报表附注 | 13 | | 财务报表附注补充资料 | 147 | 起始页码 审 计 报 告 众环审字（2025）0202061 号 海南海药股份有限公司全体股东： 一、审计意见 我们审计了海南海药股份有限公司（以下简称"海南海药公司"）财务报表，包括 2024 年 12 月 31 日的合并及公司资产负债表，2024 年度的合并及公司利润表、合并及公司现金 流量表、合并及公司股东权益变动表以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制，公允反映了 海南海药公司 2024 年 12 月 31 日合并及公司的财务状况以及 2024 年度合并及公司的经营成 果和现金流量。 二、形成审计意 ...

关于海南海药股份有限公司 2024年度营业收入扣除情况表 的专项核查报告 众环专字(2025)0201913号 目 录 起始页码 专项核查报告 营业收入扣除情况表 营业收入扣除情况表 1 我们接受委托，在审计了海南海药股份有限公司（以下简称"海南海药"）2024 年 12 月 31 日的海南海药股份有限公司的资产负债表，2024 年度合并及公司的利润表、合并及公 司的现金流量表和合并及公司的股东权益变动表以及财务报表附注（以下简称"2024 年度 财务报表"）的基础上，对后附的《海南海药股份有限公司 2024 年度营业收入扣除情况表》 （以下简称"营业收入扣除表"）进行了专项核查。 按照《深圳证券交易所股票上市规则》及《深圳证券交易所上市公司自律监管指南第 1 号——业务办理》的规定，编制和披露营业收入扣除表，提供真实、合法、完整的核查证据， 是海南海药管理层的责任。我们的责任是在执行核查工作的基础上对营业收入扣除表发表专 项核查意见。 我们按照中国注册会计师审计准则的相关规定执行了核查工作。中国注册会计师审计准 则要求我们遵守中国注册会计师职业道德守则，计划和执行核查工作以对营业收入扣除表是 否不存在重大错 ...

关于海南海药股份有限公司 在新兴际华集团财务有限公司存贷款 业务情况的专项审核报告 众环专字(2025)0201914号 目 录 起始页码 专项审核报告 1-2 存贷款业务情况汇总表 在新兴际华集团财务有限公司存贷款业务情况汇总表 1 关于海南海药股份有限公司 在新兴际华集团财务有限公司存贷款业务情况 的专项审核报告 众环专字(2025)0201914 号 海南海药股份有限公司： 我们接受委托，在审计了海南海药股份有限公司（以下简称"海南海药"）2024 年 12 月 31 日的合并及公司的资产负债表，2024 年度合并及公司的利润表、合并及公司的现金流 量表和合并及公司的股东权益变动表以及财务报表附注的基础上，对后附的《海南海药股份 有限股份公司在新兴际华集团财务有限公司存贷款业务情况汇总表》（以下简称"汇总表"） 进行了专项审核。 一、管理层对汇总表的责任 按照《深圳证券交易所上市公司自律监管指引第 7 号——交易与关联交易》的规定，编 制和披露汇总表，提供真实、合法、完整的审核证据，是海南海药管理层的责任。 二、注册会计师的责任 我们的责任是在执行审核工作的基础上对汇总表发表专项审核意见。我们按照中国注 ...